GlassScriptPhysician profile
Sheldon G Gross
NPI 1922001395
$4,254.11
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,501 · 2020: $1,663 · 2021: $697 · 2022: $189 · 2023: $21.49 · 2024: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $187 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $186.79 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,574.21 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $812.97 | 2019-2022 | |
| Livanova USA, INC. | $674.23 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $273.85 | 2019-2022 | |
| Greenwich Biosciences, INC. | $166.13 | 2019-2021 | |
| Tris Pharma INC | $152.26 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $135.69 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $120.61 | 2019 | |
| Zogenix INC. | $94.73 | 2021 | |
| Sk Life Science, INC. | $87.89 | 2021 | |
| Immedica Pharma US, INC. | $39.87 | 2023-2024 | |
| Eisai INC. | $29.57 | 2019 | |
| Ptc Therapeutics, INC. | $24.46 | 2022 | |
| Upsher-Smith Laboratories LLC | $22.15 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $16.72 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $16.52 | 2020 | |
| Aprecia Pharmaceuticals, LLC | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheldon Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.